Business Wire

AL-ADTRAN

Share
Fibernet Builds Competitive 10G Fiber Network with Adtran

Adtran, Inc. , (NASDAQ: ADTN), the leading provider of next-generation multi-gigabit fiber access and fiber extension solutions, today announced Fibernet is leveraging the Adtran 10G Fiber Access Platform to build an XGS-PON fiber network that will connect 50,000 customers in its first phase. Fibernet is leveraging its innovative fiber trenching technology to quickly build a fiber network and is using Adtran’s reliable 10G solutions to deploy competitive, scalable broadband services to households and businesses in Finland.

Fibernet is a new alternative network provider (altnet) in Finland, where much of the country can access 4G mobile broadband coverage. However, increased demand for high-bandwidth, reliable internet means that fiber connections are a necessity. While some established service providers began slowly building expensive fiber networks, Fibernet invested in an innovative fiber trenching approach that allows the altnet to build its network much faster. Fibernet selected the Adtran 10G Fiber Access Platform as its foundation to launch high-quality, competitive broadband services for internet, IPTV, telehealth and more.

“While Fibernet is new to this market, our leaders have deep experience in implementing superior broadband networks. We selected Adtran because of its experience in both the fiber access and altnet markets, and together we make a great team. We are extremely pleased with the support that Adtran has provided in our startup phase,” said Janne Ahola, CEO at Fibernet. “We understand that fiber is the only way to supply fast and reliable network connections that can scale with subscriber demands. Adtran provides a solution that can help us meet those needs today and in the future.”

The Adtran 10G Fiber Access Platform leverages the symmetrical upload and download speeds of XGS-PON technology, which future-proofs the network against growing demand for high-bandwidth cloud and streaming services. Adtran’s supply availability is also a differentiator for Fibernet. In Finland, the ground is frozen for five months each year. The long winters require well-planned building seasons and hardware deliveries must be on schedule during the warmer months. Adtran offers a comprehensive end-to-end access portfolio that allows Fibernet to order most of the hardware from a single vendor to better ensure on-time deliveries.

“Fibernet has a key advantage with its micro-trenching technology that lets it build its fiber network much faster. With Adtran in its network, Fibernet can match that innovation with a 10G fiber access platform that will provide reliable, high-quality services today and grow with them as subscriber demands evolve,” said Stuart Broome, Vice President of Sales, EMEA at Adtran. “The ease of scalability will enable Fibernet to increase capacity and scale services beyond its traditional residential subscriber base to support the connectivity needs of local small- and mid-sized businesses as well.”

For more information about the Adtran 10G Fiber Access Platform , visit www.adtran.com/fiber-access .

About Adtran

Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are currently in use by service providers, private enterprises, government organizations and millions of individual users worldwide. Find more at Adtran , LinkedIn and Twitter .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release

Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye